- Home
- SANA vs KROS Comparison
SANA vs KROS Comparison
Compare SANA & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANA
- KROS
- Stock Information
- Founded
- SANA 2018
- KROS 2015
- Country
- SANA United States
- KROS United States
- Employees
- SANA N/A
- KROS N/A
- Industry
- SANA Medicinal Chemicals and Botanical Products
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- SANA Health Care
- KROS Health Care
- Exchange
- SANA Nasdaq
- KROS Nasdaq
- Market Cap
- SANA 519.8M
- KROS 465.2M
- IPO Year
- SANA 2021
- KROS 2020
- Fundamental
- Price
- SANA $1.63
- KROS $10.04
- Analyst Decision
- SANA Strong Buy
- KROS Buy
- Analyst Count
- SANA 5
- KROS 12
- Target Price
- SANA $9.50
- KROS $27.86
- AVG Volume (30 Days)
- SANA 3.8M
- KROS 708.7K
- Earning Date
- SANA 05-07-2025
- KROS 05-07-2025
- Dividend Yield
- SANA N/A
- KROS N/A
- EPS Growth
- SANA N/A
- KROS N/A
- EPS
- SANA N/A
- KROS N/A
- Revenue
- SANA N/A
- KROS $3,550,000.00
- Revenue This Year
- SANA N/A
- KROS $65.83
- Revenue Next Year
- SANA N/A
- KROS $1.36
- P/E Ratio
- SANA N/A
- KROS N/A
- Revenue Growth
- SANA N/A
- KROS 2250.99
- 52 Week Low
- SANA $1.48
- KROS $9.41
- 52 Week High
- SANA $10.50
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- SANA 33.34
- KROS 35.08
- Support Level
- SANA $2.18
- KROS $11.18
- Resistance Level
- SANA $2.43
- KROS $11.63
- Average True Range (ATR)
- SANA 0.26
- KROS 0.42
- MACD
- SANA -0.08
- KROS -0.09
- Stochastic Oscillator
- SANA 9.84
- KROS 26.69
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.